Clinical-stage biotech developing cancer immunotherapies targeting the WT1 tumor antigen for blood and solid cancers.
Clinical-stage biotech developing cancer immunotherapies targeting the WT1 tumor antigen for blood and solid cancers.
Has no product sales: it is funded by money raised from investors, so cash runway and each round of financing matter. Galinpepimut-S is its lead drug in a late-stage trial in acute myeloid leukaemia, where results decide whether it can seek approval or a partner.
Moat: none (IP / patents). Pre-revenue biotech; success depends entirely on unproven late-stage trial outcomes.
Headquarters: New York, New York, US · Founded: 2017 · Employees: 13
Size SELLAS Life Sciences (SLS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.66B, the 1395th largest of 3,085 United States companies the cockpit tracks. Shares closed at $17.95 on 18 Nov 2026.
Performance Over six months the shares gained 100.1%, against +1.6% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 19 in its peer set.
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $1.00M |
| Revenue growth | — | — | — | -100% | — |
| Gross profit | $0 | $0 | $0 | $0 | $443,000 |
| EBITDA | -$39.4M | -$28.3M | -$31.5M | -$37.9M | -$31.5M |
| Net income | -$35.8M | -$26.9M | -$30.9M | -$37.3M | -$41.3M |
| Free cash flow | -$27.3M | -$28.4M | -$35.4M | -$36.9M | -$28.3M |
| Capital expenditure | $0 | $0 | $0 | $5.50M | $4.50M |
| Total debt | $599,000 | $1.00M | $1.00M | $906,000 | $945,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| SELLAS Life Sciences SLS | $3.66B | +100% | n/a | n/a | n/a | n/a |
| Bristol Myers Squibb BMY | $122B | +3% | +4% | 33% | 3.1× | -13.1% |
| Merck & MRK | $340B | +23% | +5% | 18% | 5.7× | 8.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SLS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +49.8% | -0.2% | highest of 21 |
| 6-month return | +100.1% | +1.6% | highest of 19 |
| Distance from 52-week high | -27.9% | -23.4% | 8th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SELLAS Life Sciences SLS | United States | $3.66B | +100% | n/a | n/a | n/a | n/a | n/a |
| Organon & OGN | United States | $3.66B | +3% | -3% | 20% | 1.8× | -4.1% | -1.0% |
| Xenon Pharmaceuticals XENE | United States | $3.71B | -31% | -100% | n/a | n/a | n/a | n/a |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.61B | 0% | +10% | 12% | 3.2× | 6.4% | +5.9% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.60B | -7% | +8% | 4% | 0.6× | -4.9% | +7.8% |
| Livzon Pharmaceutical 1513.HK | Hong Kong | $3.73B | -9% | -10% | 19% | 2.3× | -7.0% | +2.0% |
| Tarsus Pharmaceuticals TARS | United States | $3.74B | +17% | +86% | -10% | 5.2× | 34.7% | +159.5% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.75B | +12% | +14% | 20% | 4.2× | 1.2% | +12.1% |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $3.75B | -10% | -13% | 20% | 5.1× | 16.2% | -5.8% |
| Wockhardt WOCKPHARMA.NS | India | $3.52B | +25% | +26% | 13% | 9.3× | 58.0% | +4.2% |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $3.81B | -38% | +227% | 74% | 5.5× | 0.9% | +45.1% |
| Siegfried SFZN.SW | Switzerland | $3.51B | -17% | +4% | 16% | 2.8× | n/a | n/a |
| Acutaas Chemicals ACUTAAS.NS | India | $3.50B | +38% | +45% | 36% | 20.4× | n/a | n/a |
| Shanghai Junshi Biosciences 1877.HK | Hong Kong | $3.49B | -38% | +36% | -14% | 8.4× | n/a | n/a |
| Arcutis Biotherapeutics ARQT | United States | $3.49B | +35% | +60% | 7% | 6.6× | 49.2% | +367.3% |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.48B | +8% | +3% | 19% | 3.1× | -2.1% | +12.0% |
| Amylyx Pharmaceuticals AMLX | United States | $3.42B | +93% | +100% | n/a | n/a | n/a | n/a |
| Viridian Therapeutics VRDN | United States | $3.42B | +71% | -63% | -1,781% | 106.6× | n/a | n/a |
| Novast Laboratories 301569.SZ | China | $3.92B | n/a | +3% | 27% | 27.6× | 57.4% | +3.1% |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.42B | -5% | +27% | 18% | 2.6× | -3.4% | +10.6% |